Why some people with APOE4 develop Alzheimer's while others stay healthy
Study Susceptibility and Resistance to ApoE4 in Alzheimer's Disease
['FUNDING_R01'] · J. DAVID GLADSTONE INSTITUTES · NIH-11297482
This work looks at how the APOE4 gene changes brain activity and biology in ways that raise Alzheimer's risk and why some people with APOE4 remain symptom-free.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | J. DAVID GLADSTONE INSTITUTES (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11297482 on ClinicalTrials.gov |
What this research studies
From my perspective as someone concerned about Alzheimer's, the team compares animals engineered to carry the human APOE4 gene with those carrying APOE3 to find brain and molecular differences tied to memory loss. They focus on memory-related brain rhythms called sharp wave ripples and slow gamma activity, and link those signals to changes in amyloid handling and other cell processes. The researchers also study why a subset of APOE4 carriers stay free of dementia despite their genetic risk, aiming to identify protective mechanisms. Findings could point to specific molecular targets or brain processes to guide new prevention or treatment ideas.
Who could benefit from this research
Good fit: Ideal candidates would be people who carry one or two copies of the APOE ε4 allele, especially older adults or those with family history or early memory concerns.
Not a fit: People who do not carry APOE4 or whose cognitive problems are caused by non-Alzheimer conditions are less likely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could identify drug targets or brain-based strategies to prevent or delay Alzheimer's in people who carry APOE4.
How similar studies have performed: Past clinical trials targeting amyloid have largely failed, while APOE4-focused approaches have shown promising results in animal studies but remain unproven in humans.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- J. DAVID GLADSTONE INSTITUTES — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUANG, YADONG — J. DAVID GLADSTONE INSTITUTES
- Study coordinator: HUANG, YADONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia